Plain-English translation of NCT06422403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether three immune-boosting cancer medications—nivolumab, pembrolizumab, and atezolizumab—work just as well when given less frequently (extended dosing interval) compared to the standard dosing schedule. The study focuses on patients with advanced stomach, gastroesophageal junction, esophageal, liver, or lung cancer who have not received this type of treatment before. If the medication works well on a less frequent schedule, it could mean fewer clinic visits and injections for patients while maintaining the same benefits.
Immune checkpoint inhibitors have become important treatments for advanced cancers, but patients currently need frequent doses, which means many clinic visits and potential side effects from cumulative drug exposure. Researchers want to see if spacing out doses more would be just as effective, potentially reducing treatment burden on patients and healthcare systems.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of the study medications—either on the standard dosing schedule or on an extended (less frequent) dosing schedule. Depending on your cancer type, you might receive the medication alone or combined with other chemotherapy or drugs. You would attend regular clinic visits for treatment infusions or injections, blood tests to monitor your health and drug levels, and imaging scans to see if your cancer is responding. The study will track how well the medication works, any side effects, and your overall survival over time.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Singapore